GT Biopharma, Inc.
GTBP
$0.42
-$0.01-1.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -42.28% | 53.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -49.10% | 65.43% | |||
| Operating Income | 49.10% | -65.43% | |||
| Income Before Tax | 87.70% | -639.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 87.70% | -639.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 87.70% | -639.60% | |||
| EBIT | 49.10% | -65.43% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 95.00% | -169.30% | |||
| Normalized Basic EPS | 94.73% | -124.56% | |||
| EPS Diluted | 95.00% | -169.30% | |||
| Normalized Diluted EPS | 94.73% | -124.56% | |||
| Average Basic Shares Outstanding | 133.34% | 229.33% | |||
| Average Diluted Shares Outstanding | 133.34% | 229.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | 0.77% | |||